MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-23-3940

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2024

Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses.

D'Alise Anna Morena, Leoni Guido, Cotugno Gabriella, Siani Loredana, Vitale Rosa, Ruzza Valentino, Garzia Irene, Antonucci Laura, Micarelli Elisa, Venafra Veronica, Gogov Sven, Capone Alessia, Runswick Sarah, Martin-Liberal Juan, Calvo Emiliano, Moreno Victor, Symeonides Stefan N, Scarselli Elisa, Bechter Oliver

СтатьяКлиническое исследование I фазыПеревод в очереди

Аннотация

PURPOSE: Personalized vaccines targeting multiple neoantigens (nAgs) are a promising strategy for eliciting a diversified antitumor T-cell response to overcome tumor heterogeneity. NOUS-PEV is a vector-based personalized vaccine, expressing 60 nAgs and consists of priming with a nonhuman Great Ape Adenoviral vector (GAd20) followed by boosts with Modified Vaccinia Ankara. Here, we report data of a phase Ib trial of NOUS-PEV in combination with pembrolizumab in treatment-naïve patients with metastatic melanoma (NCT04990479).

PATIENTS AND

METHODS

The feasibility of this approach was demonstrated by producing, releasing, and administering to 6 patients 11 of 12 vaccines within 8 weeks from biopsy collection to GAd20 administration.

RESULTS

The regimen was safe, with no treatment-related serious adverse events observed and mild vaccine-related reactions. Vaccine immunogenicity was demonstrated in all evaluable patients receiving the prime/boost regimen, with detection of robust neoantigen-specific immune responses to multiple neoantigens comprising both CD4 and CD8 T cells. Expansion and diversification of vaccine-induced T-cell receptor (TCR) clonotypes was observed in the posttreatment biopsies of patients with clinical response, providing evidence of tumor infiltration by vaccine-induced neoantigen-specific T cells.

CONCLUSIONS

These findings indicate the ability of NOUS-PEV to amplify and broaden the repertoire of tumor-reactive T cells to empower a diverse, potent, and durable antitumor immune response. Finally, a gene signature indicative of the reduced presence of activated T cells together with very poor expression of the antigen-processing machinery genes has been identified in pretreatment biopsies as a potential biomarker of resistance to the treatment.

Для цитирования: D'Alise Anna Morena, Leoni Guido, Cotugno Gabriella, Siani Loredana, Vitale Rosa, Ruzza Valentino, Garzia Irene, Antonucci Laura, Micarelli Elisa, Venafra Veronica, Gogov Sven, Capone Alessia, Runswick Sarah, Martin-Liberal Juan, Calvo Emiliano, Moreno Victor, Symeonides Stefan N, Scarselli Elisa, Bechter Oliver. Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024. DOI: 10.1158/1078-0432.ccr-23-3940.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.